Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

R21 malaria vaccine is protective against intradermal but not intravenousPlasmodium falciparumsporozoites in a randomized controlled human malaria infection study in Kenyan adults

Kapulu MC. et al, (2024)

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.

Hanboonkunupakarn B. et al, (2024), NPJ Vaccines, 9

Validation of a multiplexed immunoassay for use in vaccine clinical trials and immunology studies of pre-erythrocytic malaria

Stockdale L. et al, (2024)

High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.

Mentzer AJ. et al, (2024), Nat Med, 30, 1384 - 1394

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.

Schmit N. et al, (2024), Lancet Infect Dis, 24, 465 - 475

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.

Datoo MS. et al, (2024), Lancet, 403, 533 - 544

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.

Jenkin D. et al, (2023), Lancet Infect Dis, 23, 956 - 964

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.

Yin Z. et al, (2023), Cell Rep, 42

Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria

Li K. et al, (2023), Biophysical journal, 122, 144a - 145a

A tool for evaluating heterogeneity in avidity of polyclonal antibodies.

Li K. et al, (2023), Front Immunol, 14

Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies.

Mugo RM. et al, (2023), PLoS One, 18

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.

Sang S. et al, (2023)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso

Morter R. et al, (2022), Frontiers in Immunology, 13

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.

Datoo MS. et al, (2022), Lancet Infect Dis, 22, 1728 - 1736

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

Madhavan M. et al, (2022), EBioMedicine, 85

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.

Jenkin D. et al, (2022), Lancet Microbe, 3, e663 - e671

High-resolution African HLA resource uncoversHLA-DRB1expression effects underlying vaccine response

Mentzer A. et al, (2022)

Vaccines against SARS-CoV-2

Noé A. and Ewer K., (2022), Vaccinology and Methods in Vaccine Research, 201 - 222

T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.

Swanson PA. et al, (2021)

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Flaxman A. et al, (2021)

Load More

Include forthcoming?